A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer

Amgen46 enrolled

Overview

This study will assess an investigational medication for patients with severe primary hyperparathyroidism or parathyroid cancer.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Hyperparathyroidism Parathyroid Neoplasms

Interventions

AMG 073DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

* Patients must have parathyroid carcinoma or severe primary hyperparathyroidism; \* Abnormally elevated calcium levels above 12.5 mg/dL; \* Not be pregnant or nursing; \* Not have had any type of cancer other than parathyroid carcinoma within the last 5 years.

Outcomes

Primary Outcomes

Changes in serum calcium and PTH

Secondary Outcomes

Safety and tolerability of cinacalcet

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.